GSK/Ranbaxy Deal Gives Indian Firm Greater Development Charge
This article was originally published in PharmAsia News
GlaxoSmithKline and Ranbaxy Laboratories broadened a 2003 agreement to give the Indian company new responsibilities for developing drug candidates, the companies announced Feb. 6
You may also be interested in...
Latest deal could bring GSK’s total price tag for December to almost $4 billion.
Epix will be eligible to earn milestones of $1.2 billion based on development and commercialization of four programs, including a Phase II Alzheimer’s molecule.
GSK’s Center Of Excellence For External Drug Discovery Head Maxine Gowen: An Interview With “The Pink Sheet” DAILY
Company's approach to biotech deals differs from big pharma competitors, Gowen says.